From Amazon.com |
Isn't it enjoyable to find an additional use for something that is already useful?
Examples that come to mind are the hanger that you 'reused' to aid in reception for your boom box when the antennae broke, the banana peel that goes into the compost pile to feed future plants rather than the garbage can, or the leftover driveway sealer bucket that can hold baseballs for BP for years to come.
At the risk of practicing zealotry (yes, I looked it up, and it is a word- ), I was looking into a few studies regarding C-Peptide, and I came across an interesting study published in the Canadian Medical Association Journal from earlier this year.
I know we have gone over a number of practical, actual and theoretical uses for the laboratory test C-Peptide in the Bariatric surgery circles in this blog. We've discussed how it can identify and predict the severity of metabolic (Diabetic) disease, and how it can predict the potential effect that bariatric surgery can have on Diabetes and the chances of its remission.
This new study was news to me, and it dealt with C-Peptide levels and the risk of death among adults without diabetes mellitus.
I understand the measurement of C-Peptide as a surrogate level for endogenous insulin secretion, and therefore pancreatic islet cell function. Not a far stretch to equate that level with either a high level (early diabetes) or a low level (once pancreatic function is in decline, implicating marked severity of diabetes - essentially creating a type 1 out of a type 2 diabetic) and it's implication on death from Cardiovascular diseases.
But, that C-Peptide levels correlated in a direct way, in Non- Diabetic patients, with the risk of death... that caught my eye.
It seems that C-Peptide may potentially be considered a bioactive peptide in it's own right.
5902 participants aged 40 years and older with no Hx of Diabetes were evaluated in terms of their baseline C-Peptide levels. The primary outcome was all-cause, cardiovascular-related and coronary artery disease mortality.
What's also interesting is that as C-Peptide rose there were significant and graded increases in mortality regardless of whether or not there were increases in the level of glycated hemoglobin and fasting glucose.
In essence, higher C-Peptide levels were associated with increased mortality among strata of glycated hemoglobin and fasting serum glucose, but also independent of those markers. Now some of these patients may have been 'pre-diabetic', with their baseline C-Peptide being the only evidence of the impending disease process, resulting from cumulative diet, aging, genetics, and increasing weight.
Given the epidemic nature of Diabetes these days, that probably represents a good chunk of the results, but there is very likely something more involved.
However, generally speaking, the levels in the study were noted to be higher in those patients with a Hx of HTN, hypercholesterolemia, or MI; and among those with a higher BMI, and with higher levels of C-reactive protein, total cholesterol, serum insulin, glycated hemoglobin, and fasting serum glucose. What else do you need for the toxic stew to end up with heart disease?
So, consider a C-peptide the next time you do those annual labs on that patient in for a followup. It could provide yet another objective data point to set the stage for 'the talk' to get them thinking about the urgency and necessity of making some changes before it's too late.
Whether or not that means that Bariatric Surgery is in their future, the main thing is that in preventing death and disease, the Heart, Brain, and Pancreas are literally of vital importance.